Influence of pregnancy, menopause and hormone substitution therapy on systemic lupus erythematosus;Influence de la grossesse, de la menopause et du traitement hormonal substitutif sur l'evolution du lupus erythemateux dissemine

Presse Medicale

Volumn 29, Issue 1, 2000, Pages 55-60

  Huong, Du Le Thi ^b   Wechsler, B ^a   Piette, J C ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b GH Pitie Salpetriere ^*

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; COMPLEMENT; CREATININE; DNA; HEPARIN; HORMONE;

CREATININE BLOOD LEVEL; FETUS RISK; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; MENOPAUSE; OVULATION INDUCTION; PREGNANCY; PROGNOSIS; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOEMBOLISM;

ASPIRIN; ESTROGEN REPLACEMENT THERAPY; FEMALE; HEPARIN; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; OVULATION INDUCTION; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 0034650395     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Lahita RG. Sex and age in systemic lupus erythematosus. In: Lahita Editor. Systemic Lupus Erythematosus. New York. Wiley 1998.
2. Yell JA, Burge SM. The effect of hormonal changes on cutaneous disease in lupus erythematosus. Br J Dermatol 1993 ; 129:18-22.
3. Roubinian J, Talal N, Greenspan JS, Goodman JR, Siteri PK: Effect of castration and sex hormone treatment on survival, antinucleic acid antibodies, and glomerulonephritis in NZB/NZW F1 mice. J Exp Med 1978 ; 147:1568-83.
4. Le Thi Huong D, Papo T, Beaufils H et al. Renal involvement in systemic lupus erythematosus. A study of 180 patients from a single center. Medicine 1999 ; (sous presse).
5. Lockshin MD. Pregnancy does not cause system c lupus erythematosus to worsen. Arthritis Rheum 1989 ; 32:665-70.
6. Wechsler B, Le Thi Huong D, Piette JC. Grossesse et lupus érythemateux systémique. Ann Méd Interne 1999 ; (sous presse).
7. Mintz G, Niz J, Guttierez G, Garcia-Alonso A, Karchmer S. Prospective study of pregnancy n systemic lupus erythematosus: results of a multidisciplinary approach. J Rheumatol 1986 ; 13:732-9.
8. Urowitz MB, Gladman DD, Farewell VT, Stewart J, McDonald J. Lupus and pregnancy studies Arthritis Rheum 1993 ; 10:1392-7.
9. Petri M, Howard D, Repke J. Frequency of lupus flare in pregnancy. The Hopkins lupus pregnancy center experience. Arthritis Rheum 1991 ; 34:1538-45.
10. Ruiz-Irastorza G, Khamashta MA, Hughes GRV. Lupus flare during pregnancy. Arthritis Rheum 1998 ; 41(suppl) S65 abtract 198.
11. Le Thi Huong D, Wechsler B, Piette JC, Blétry O, Godeau P. Pregnancy and its outcome in systemic lupus erythematosus. Q J Med 1994 ; 87:721-9.
12. Minakami H, Idei S, Koike T, Tamada T, Yasuda Y, Hirota N. Active lupus and preeclampsia: A life threatening combination. J Rheumatol 1994 ; 21:1562-3.
13. Alsukyman OM, Castro MA, Zuckerman E, McGehee W, Goodwin TM. Preeclampsia and liver infarct on in early pregnancy associated with antiphospholic syndrome. Obstet Gynecol 1996 ; 88:644-6.
14. Magann EF, Perry KG, Meydrech EF, Harris RL, Chauhan SP, Martin JN. Postpartum corticosteroids: Accelerated recovery from the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP). Am J Obstet Gynecol 1994 ; 171:1154-8.
15. Abramson SB, Buyon JP. Activation of the complement pathway: comparison of normal pregnancy, preeclampsia and systemic lupus erythematosus during pregnancy Am J Reprod Immunol 1992 ; 28:183-7.
16. Petri M. Systemic lupus erythematosus and pregnancy. Rheum Clin North Am 1994 ; 20:87-118.
17. Tomer Y, Viegas OAC, Swissa M, Koh SCL, Shoenfeld Y. Levels of lupus autoantibodies in pregnant SLE patients: Correlations with disease activity and pregnancy outcome. Clin Exp Rheumatol 1996 ; 14:275-80.
18. The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991 ; 324:150-4.
19. Jungers P, Chauveau D. Pregnancy in renal disease. Kidney Int 1997 ; 52:871-85.
20. Rahman P, Gladman DD, Urowitz MB. Clinical predictors of fetal outcome in systemic lupus erythematosus. J Rheumatol 1998 ; 25:1526-30.
21. Imbasciati E, Suriar M, Bottno et al. Lupus nephritis and pregnancy. A study of 26 pregnancies in patients with systemic lupus erythematosus and nephritis. Nephron 1984 ; 36:46-51.
22. Cameron JS, Hicks J. Pregnancy in patients with pre-existing glomerular disease. Contrib Nephrol 1984 ; 37:149-56.
23. Oviasu E, Hicks J, Cameron JS. The outcome of pregnancy in women with lupus nephritis. Lupus 1991 ; 1:19-25.
24. Packham DK, Lam SS, Nicholls K, Fairley KF, Kincaid-Smith PS. Lupus nephritis and pregnancy. Q J Med 1992 ; 83:315-24.
25. Lima F, Khamashta MA, Buchanan NMM, Kerslake S, Hunt BJ, Hughes GRV. A study of sixty pregnancies in the patients with the antiphospholipid syndrome. Clin Exp Rheumatol 1996 ; 14:131-6.
26. Hussein MM, Mooij JM, Roujouleh H. Cyclosporir in the treatment of lupus nephritis including two patients treated during pregnancy. Clin Nephrol 1993 ; 40:160-3.
27. Toyota T, Yorioka N, Takahashi N et al. Successful birth in a hemodialys s patient with SLE. Nephron 1993 ; 65:331-2.
28. Le Thi Huong D, Wechsler B, Vauthier-Brouzes D et al. La grossesse au cours de la néphropathie lupique. Rev Méd Interne 1998 ; 19(suppl 1):75s.
29. Laskin CA, Bombardier C, Hannah ME et al. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. N Engl J Med 1997 ; 337:148-53.
30. Soulier JP, Boffa C. Avortements à répétition, thromboses et anticoagulant circulant anti-thromboplastine. Presse Med 1980 ; 9:859-64.
31. Weber JC. Les complications obstétricales du syndrome des antiphospholipides. Rev Méd Interne 1997 ; 18:240-9.
32. Ruiz-Irastorza G, Khamashta M, Hughes G. Treatment of the antiphospholipid syndrome in pregnancy. Scand J Rheumatol 1998 ; 27(suppl):44-7.
33. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996, 174:1584-9.
34. Ramsey-Goldman R, Kutzer JE, Kuller LH, Guzick D, Betts Carpenter A, Medsger TA. Pregnancy outcome and anti-cardiolipin antibody in women with systemic lupus erythematosus. Am J Epidemiol 1993 ; 138:1057-69.
35. Branch DW, Silver RM. Criteria for antiphospholipd syndrome: early pregnancy loss, fetal loss, or recurrent pregnancy loss? Lupus 1996 ; 5:409-13.
36. Nayar R, Lage JM. Placental changes in a first trimester missed abortion in maternal lupus erythematosus with antiphospholipid syndrome. Hum Pathol 1996 ; 27:201-6.
37. Hasegawa I, Takakuwa K, Goto S et al. Effectiveness of prednisone/aspirin therapy for recurrent aborters with antiphospholipid antibody. Hum Reprod 1992 ; 7:203-7.
38. Rai R, Clifford K, Cohen H, Regan L. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarrage and antiphospholipid antibodies. Hum Reprod 1995; 10:3301-4.
39. Rosove MH, Tabsh K, Wasserstrum N, Howard P, Hahn BH, Kalunian KC. Heparin therapy for pregnant women with lupus anticoagulant or anticardiolipin antibodies. Obstet Gynecol 1990 ; 75:630-4.
40. Branch DW, Silver RM, Blackwell JL, Reading JC, Scott JR. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol 1992 ; 80:614-20.
41. Schiff E, Mashiach S. The use of low dose aspirin in pregnancy. Am J Reprod Immunol 1992 ; 28:153-6.
42. Sibai BM, Caritis SN, Thom E et al. Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. N Engl J Med 1993 ; 329:1213-8.
43. Krnic-Barrie S, OConnor CR, Looney SW, Pierangeli SS, Harris EN. A retrospective review of 61 patients with antiphospholipid syndrome: Analysis of factors influencing recurrent thrombosis. Arch Intern Med 1997 ; 157:2101-10.
44. Thorp JM, Chescheir NC, Fann B. Postpartum myocardial infarction in a patient with antiphospholipid syndrome. Am J Perinatol 1994 ; 11:1-3.
45. Carreras LO, Defreyn G, Machin SJ et al. Arterial thrombosis, intrauterine death and "lupus" anticoagulant: detection of immunoglobulin interfering with prostacyclin formation. Lancet 1981 ; 31:244-6.
46. Kincaid-Smith P, Fairley KF, Kloss M. Lupus anticoagulant associated with renal thrombotic microangiopathy and pregnancy-related renal failure. Q J Med 1988 ; 69:795-815.
47. Kupferminc MJ, Lee MJ, Green D, Peaceman AM. Severe post-partum pulmonary, cardiac, and renal syndrome associated with antiphospholipid antibodies. Obstet Gynecol 1994 ; 83:806-7.
48. Asherson RA, Cervera R, Piette JC et al. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine 1998 ; 77:195-207.
49. Le Thi Huong D, Wechsler B, Edelman P et al. Postpartum cerebral infarction associated with aspirin withdrawal in the antiphospholid antibody syndrome. J Rheumatol 1993 ; 30:1229-32.
50. Silver RM, Draper ML, Scott JR, Lyon JL, Reading J, Branch W. Clinical consequences of antiphospholipid antibodies: an historic cohort study. Obstet Gynecol 1994 ; 83:372-7.
51. Branch W. Antiphospholipid antibodies and reproductive outcome: the current state of affairs. J Reprod Immunol 1998 ; 38:75-87.
52. Wechsler B, Le Thi Huong D, Vauthier-Brouzes D, Lefebvre G, Gompel A, Piette JC. Can we advise ovulation induction in patients with SLE ? Scand J Rheumatol 1998 ; 27(suppl):53-9.
53. Le Thi Huong D, Wechsler B, Piette JC et al. Risks of ovulation-induction therapy in systemic lupus erythematosus. Br J Rheumatol 1996 ; 35:1184-6.
54. Ben-Chetrit A, Ben-Chetrit E. Systemic lupus erythematosus induced by ovulation induction treatment. Arthritis Rheum 1994 ; 37:1614-7.
55. Casoli P, Tumiati B, La Sala G. Fatal exacerbation of systemic lupus erythematosus after induction of ovulation. J Rheumatol 1997 ; 24:1639-40.
56. Miyagawa S, Shirai T, Shimamoto I, Ichijo M, Ueki H. Worsening of systemic lupus erythematosus-associated thrombocytopenia after administration of gonadotropin-releasing hormone analog. Arthritis Rheum 1994 ; 37:1708-9.
57. Ward MM, Pyun E, Studenski S. Causes of death in systemic lupus erythematosus. Arthritis Rheum 1995 ; 38:1492-9.
58. Ward MM, Plisson RP. A meta-analysis of the clinical manifestations of older-onset systemic lupus erythematosus. Arthritis Rheum 1989 ; 32:1226-32.
59. Mok CC, Lau CS, Wong RWS. Menopause and flares of systemic lupus erythematosus. Arthritis Rheum 1998 ; 41(suppl):S65 abstr 195.
60. Sanchez-Guerrero J, Villegas A, Mendoza-Fuentes A, Romero-Diaz J. Effect of menopause over disease activity in systemic lupus erythematosus. Arthritis Rheum 1998 ; 41(suppl):S66 abstr 204.
61. Baker SB, Rovira JR, Campion EW, Mills JA. Late onset of systemic lupus erythematosus. Am J Med 1979 ; 66:727-32.
62. Wallace DJ, Podell T, Weiner J, Klinenberg JR, Forouzesh S, Dubois EL. Systemic lupus erythematosus - survival patterns. Experience with 609 patients. JAMA 1981 ; 245:934-8.
63. Fenichel P, Sosset C, Barbarino-Monnier P et al. Prevalence, specificity and significance of ovarian antibodies during spontaneous premature ovarian failure. Hum Reprod 1997 ; 12:2623-8.
64. Mok CC, Lau CS, Woon Sing Wong R. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum 1997 ; 41:831-7.
65. Boumpas DT, Austin HA, Vaughan EM, Yarboro CH, Klippel JH, Balow JE. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993 ; 119:366-9.
66. Mok CC, Lau CS, Ho CT, Lee KW, Mok MY, Wong RW. Safety of hormonal replacement therapy in postmenopausal patients with systemic lupus erythematosus. Scand J Rheumatol 1998 ; 27:342-6.
67. Petri M, Perez-Gutthann S, Spence D, Hochberg M. Risk factors for coronary artery disese in patients with systemic lupus erythematosus. Am J Med 1992 ; 93:513-9.
68. Bukley BH, Roberts WC. The heart in systemic lupus serythematosus and the changes induced in it by corticosteroid therapy: a study of 36 necropsy patients. Am J Med 1975 ; 58:243-64.
69. Sanchez-Guerrero J, Liang MH, Karlson EW, Hunter DJ, Colditz GA. Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus. Ann Intern Med 1995 ; 122:430-3.
70. Piette JC, Le Thi Huong D, Papo T. Postmenopausal hormone therapy and systemic lupus erythematosus. Ann Intern Med 1995 ; 123:961-2.
71. Arden NK, Lloyd ME, Specter TD, Hughes GRV. Safety of hormone replacement therapy in systemic lupus erythematosus. Lupus 1994 ; 3:11-3.
72. Kreidstein S, Urowitz MB, Gladmann DD, Gough J. Hormonal replacement therapy in systemic lupus erythematosus. J Rheumatol 1997 ; 24:2149-52.
73. Petri M, Buyon J, Kim M. Differences in pre vs post-menopausal SLE: the SELENA Trial. Arthritis Rheum 1998 ; 41(suppl):S67 abstr 206.